Friday, 16 October 2026European Markets

MPC CONTAINER SHIP Stock Over 21% Up In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of MPC CONTAINER SHIP (Oslo Børs Benchmark Index_GI: MPCC.OL) rose by a staggering 21.16% in 10 sessions from kr17.01 to kr20.61 at 14:43 EST on Monday, after four sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI is dropping 0.29% to kr1,215.57, after three successive sessions in a row of losses.

MPC CONTAINER SHIP's last close was kr20.61, 25.7% under its 52-week high of kr27.74.

About MPC CONTAINER SHIP

MPC Container Ships ASA owns and operates a portfolio of container vessels. The company focuses on small-to mid-size vessels that are chartered out on time-charter contracts to global and regional liner shipping companies serving intra-regional trade lanes. It operates a fleet of 62 vessels with an aggregate capacity of approximately 134,270 twenty-foot equivalent units. MPC Container Ships ASA was incorporated in 2017 and is based in Oslo, Norway.

Earnings Per Share

As for profitability, MPC CONTAINER SHIP has a trailing twelve months EPS of kr10.97.

PE Ratio

MPC CONTAINER SHIP has a trailing twelve months price to earnings ratio of 1.88. Meaning, the purchaser of the share is investing kr1.88 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 59.57%.

Growth Estimates Quarters

The company's growth estimates for the current quarter and the next is a negative 90.4% and a negative 93.1%, respectively.

More news about MPC CONTAINER SHIP (MPCC.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com